MINIMAL RESIDUAL DISEASE DETECTION IN CHILDHOOD ALL

儿童期最小残留疾病检测

• 批准号: 2896675
• 负责人: MICHAEL J BOROWITZ
• 金额: $ 5.03万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2000-04-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2896675
• 关键词: B lymphocyte; acute lymphocytic leukemia; bone marrow; cancer registry /resource; cellular oncology; child (0-11); clinical research; cooperative study; disease /disorder proneness /risk; flow cytometry; human therapy evaluation; human tissue; immunofluorescence technique; minimal residual disease; neoplasm /cancer immunodiagnosis; neoplasm /cancer relapse /recurrence; neoplasm /cancer remission /regression; neoplastic cell; pediatric neoplasm /cancer; phenotype; prognosis

DESCRIPTION (Applicant's Description): Although the cure rate of childhood ALL is among the highest of any cancers, there is still significant room for improvement both because some children still succumb to their disease and because others may obtain more treatment than is necessary for cure. Almost all children enter remission following initial therapy, but many patients harbor residual disease below the level that can be detected by conventional measurements, and there is a growing body of evidence that presence of this minimal residual disease may be an adverse prognostic factor. This project is designed to study a series of patients with B-precursor ALL enrolled on the Pediatric Oncology Group ALinC 17 pilot studies for newly diagnosed ALL in children. In this study we hypothesize that we will be able to distinguish leukemic cells from normal cells based on their abnormal phenotype using flow cytometry. In preliminary studies we have shown that we can detect leukemic cells at a level of up to 1/10,000 normal cells in virtually all cases of B-precursor ALL using a relatively simple four color flow cytometry assay. We will use this assay to determine how often cells with these phenotypes can be detected in patients in remission at the end of both induction therapy and consolidation therapy. In addition, we will determine if the presence of MRD at either of these times correlates with other clinical and laboratory risk factors or with the rate of relapse of leukemia. We recognize that the latter objective will not be answered definitively by this two year pilot study. If this pilot is successful, however, we will obtain a definitive answer from a subsequent study of over 2000 patients, and be able to design subsequent intervention studies to investigate if patients can benefit from specific therapy based on the presence of minimal residual disease.

描述（申请人的描述）：尽管童年的治愈率 一切都是癌症中最高的，仍然有很大的空间 两者都改善，因为有些孩子仍然屈服于他们的疾病， 因为其他人可能获得的治疗比治愈所需的治疗更多。 几乎 所有儿童在初次治疗后都会入围缓解，但许多患者 港口残留疾病低于常规的水平 测量结果，并且越来越多的证据表明存在 最小残留疾病可能是不良预后因素。 这个项目 旨在研究一系列B-Exursor的患者均参与 小儿肿瘤学组ALINC 17新诊断的试点研究 在儿童中。 在这项研究中，我们假设我们将能够 根据其异常区分白血病细胞和正常细胞 使用流式细胞术表型。 在初步研究中，我们表明 我们可以在多达1/10,000个正常细胞的水平上检测白血病细胞 几乎所有b-ecursor的案例都使用相对简单的四种颜色 流式细胞仪测定法。 我们将使用该测定法来确定单元格的频率 使用这些表型可以在患者的缓解中检测到 诱导疗法和巩固疗法。 此外，我们将 确定在这两个时间中，MRD的存在是否与 其他临床和实验室危险因素或随着复发率 白血病。 我们认识到后一个目标不会回答 这项为期两年的试点研究明确。 如果这个飞行员成功， 但是，我们将从随后的研究中获得明确的答案 2000名患者，并且能够设计随后的干预研究 调查患者是否可以根据特定疗法受益 存在最小残留疾病。